BofA Securities lowers UnitedHealth price target to $300 on slower recovery

Published 29/07/2025, 17:36
BofA Securities lowers UnitedHealth price target to $300 on slower recovery

Investing.com - BofA Securities has reduced its price target on UnitedHealth Group (NYSE:UNH) to $300.00 from $350.00 while maintaining a Neutral rating on the stock. The stock, currently trading at $267.43, has experienced a significant decline of nearly 47% over the past six months, according to InvestingPro data.

The price target adjustment reflects BofA’s assessment that UnitedHealth’s pace of improvement will likely be slower than previously expected, according to analyst notes from the firm.

UnitedHealth has communicated expectations for "solid but moderate" earnings growth in 2026, with acceleration anticipated in 2027 and subsequent years, the research note indicated.

While the healthcare giant did not explicitly confirm its long-term growth target of 13-16%, BofA noted that the company pointed toward eventually returning to "low double-digit ranges" and historical growth levels. This outlook is based on "reasonable growth from well run businesses, compounding efficiency gains, deploying capital for shareholders and M&A."

BofA Securities also highlighted that UnitedHealth has become "much more open about segment margins and issues," which the firm believes creates better understanding of the company’s business drivers.

In other recent news, UnitedHealth Group’s second-quarter earnings call disclosed a mixed financial performance. The company reported earnings per share (EPS) of $4.08, which fell short of the anticipated $4.45, representing an 8.31% surprise miss. Despite this, UnitedHealth saw a 13% increase in revenue year-over-year, reaching $112 billion. This earnings miss has raised concerns among investors. There were no significant mergers or acquisitions announced during this period. Analyst firms have yet to provide any upgrades or downgrades following the earnings report. UnitedHealth’s financial results are part of the latest developments affecting the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.